Newark, CA, March 18, 2019 – FlemingMartin is pleased to announce that Revance Therapeutics (NASDAQ: RVNC), a pioneering biotechnology company focused on the development and commercialization of botulinum toxin products for cosmetic and therapeutic applications, has hired Dr. Atul Mahableshwarkar to be their new Vice President of Clinical Development for the Therapeutics Portfolio.

Dr. Mahableshwarkar brings exceptional neurology expertise and clinical development leadership experience to Revance from more than 15 years with BlackThorn Therapeutics, Takeda Pharmaceutical Co., GlaxoSmithKline, and Janssen Pharmaceuticals. Over his distinguished career, Dr. Mahableshwarkar has played a critical role in the global development and regulatory approval of multiple drugs for neurobehavioral disorders, including Takeda’s Trintellix (vortioxetine), a serotonin modulator for the treatment of major depressive disorder (MDD). Most recently, as Vice President of Clinical Development at BlackThorn, Dr. Mahableshwarkar led development programs for Major Depression, Parkinson’s, and Anxiety Disorders.

Dr. Mahableshwarkar holds an MBBS from Armed Forces Medical College in India and he completed a residency in general adult psychiatry and a fellowship in neuropsychiatry at The Chicago Medical School.

 

Revance Therapeutics (NASDAQ: RVNC) is a pioneering biotechnology company committed to the advancement of remarkable science. The Company is poised to enter, and potentially redefine, the neuromodulator aesthetic and therapeutic product categories. Revance’s proprietary peptide technology, when combined with active drug molecules, may help address current unmet needs in dermatology, neurology, and musculoskeletal disorders.

 

FlemingMartin is a leading retained executive search firm with offices in Northern and Southern California. FlemingMartin partners with Boards, Private Equity Firms, and CEOs to build successful execution-focused management teams. The Firm’s principals are trusted advisors and business partners who enable companies to gain powerful, far-reaching, and lasting contributions from their executive-level human capital.